Aurobindo Pharma Limited — Q4 FY24
Aurobindo Pharma delivered a strong Q4 FY24 with revenue of INR 7,850 crore (+17% YoY) and EBITDA of INR 1,687 crore (+68% YoY), driven by volume gains, new product launches, st...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
FY24 EBITDA margin target of 20%
Management reiterated confidence in achieving 20% EBITDA margin for FY24, supported by operational efficiencies and cost improvements.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Eugia Unit III production restart timeline
Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1